We have used a recombinant adenovirus vector (E1 ) expressing -galactosidase to explore a novel mechanism with which to transfer genes into cells of the central nervous system (CNS). The replication-deficient adenovirus vector expressing -galactosidase (RAd35) was propagated on a permissive helper cell line (293 cells). High level protein expression from the human cytomegalovirus immediate early promoter (hCMV IE) was obtained in a target cell population of RAd35 infected cultured neuronal and glial cell lines. Light microscopy showed that over 50% of the glial cells studied expressed -galactosidase. Following retinoic acid treatment, RAd35 infected cell lines ND7/23, NG108 and NTera2, showed -galactosidase expression in up to 90% of the cells. In addition, these cells showed morphological evidence of differentiation into neurons. This pattern of -galactosidase expression was also observed in primary rat cerebella granule neuron cultures. In vivo studies were performed in Balb/c mice following direct intracranial injections of RAd35 into the brain. Cell sections showed a localised staining in the brain at the site of injection of the virus. Non-replicating adenovirus vectors are therefore highly efficient systems for delivering a transgene into brain cells. However, their broad cell tropism may limit their applications for genetic disorders in which a specific cell type is to be targeted for gene therapy. To address this problem, we have constructed adenovirus vectors which contain specific neuronal promoters and are currently assessing in vitro expression.
Introduction
The adenovirus genome has been studied and the complete DNA sequence of several serotypes is known. Currently, forty nine distinct human serotypes of adenovirus have been determined. They are non-enveloped isometric particles with icosahedral symmetry which contain a double stranded DNA genome, 36 kilobases long encoding late gene structural proteins (Blair et al., 1995) .
Replication-deficient adenovirus vectors have become a commonly used viral vector expression system for use in immunisation schedules for novel vaccine design (reviewed in Randrianarison-Jewtoukoff and Perricaudet, 1995) . Replicating adenoviruses have also been successfully used in human trials as vaccines for use by American troops to protect them against acute respiratory disease ( Rubin and Rorke, 1994) .
Previous studies in our laboratory have shown that replication-deficient adenovirus vectors are highly effective for expressing foreign proteins. We have shown high level expression of the reporter genegalactosidase (Wilkinson and Akrigg, 1992; Sivasubramaniam et al., 1997) , the measles virus nucleocapsid, haemagglutinin and fusion proteins in primary human fibroblasts (Fooks et al., 1995; Fooks, unpublished results) .
In this study, we have used a replication-deficient adenovirus vector expressing the reporter genegalactosidase (RAd35) as a model system to firstly, determine the cell tropism for adenoviruses and secondly, to assess the in vivo transfer of genes into CNS cells. The recombinant adenovirus vector (RAd35) was constructed by cloning the reporter gene -galactosidase from the lacZ gene of Escherichia coli. The -galactosidase gene was selected as the reporter gene because the expression of this reporter enzyme can be readily detected, and there is little or no interference or competition from other enzymes. Gene therapy provides a possible alternative treatment to inherited monogenic disorders affecting the CNS. The successful introduction of the genes into cells may assist in controlling certain genetic diseases, in which only a minority of cells may need to be infected to replace a deficient enzyme in sufficient quantities for in vivo therapy. Recently, the treatment of human genetic disorders using adenovirus vectors has been mediated by gene transfer technology especially for genetic disorders involving single gene mutations (reviewed in Wilkinson, 1994) .
Materials and methods

Cells and viruses
All cell lines used in this study are listed in Table 1 and were obtained from ECACC, UK (except the primary cells). All cell lines used were mycoplasma negative by Hoechst stain and culture (Dr. A. Stacey, ECACC, personal communication). Cells were cultured in complete Dulbecco's modified Eagles's medium (Sigma, Poole, UK), supplemented with 10% (v/v) foetal calf serum (FCS) (PAA, Linz, Austria) and 0.03% (w/v) L-glutamine (Sigma, Poole, UK), at 37 C except that NG108-15 was supplemented with 2% hypoxanthine aminopterin thymidine (2% HAT). Human brain astrocytoma cells (MO-GG-CC-M) were grown in HAMS F10 complete growth media (Sigma, Poole, UK) supplemented with 10% (v/v) foetal calf serum (FCS) (PAA, Linz, Austria) and 0.03% (w/v) L-glutamine (Sigma, Poole, UK) and cultured at 37 C. The adenovirus recombinant (RAd35) was propagated and titrated in 293 cells as previously described (Warnes and Fooks, 1996) . Enhanced expression from the CMV IE promoter was achieved by chemical induction of the promoter using forskolin at a final concentration of 10 M in tissue culture medium where required.
The adenovirus recombinant (RAd35) expressing the reporter gene -galactosidase is under the control of the strong human cytomegalovirus immediate early promoter (hCMV IE) promoter. RAd31 is an adenovirus vector containing the CMV IE promoter/terminator cassette as previously described (Wilkinson and Akrigg, 1992) . All cells were infected at an m.o.i. of 100 pfu/cell using previously reported protocols (Warnes and Fooks, 1996) .
Primary cell isolation from rat cerebellum
Seven day old rat pups (strain Sprague-Dawley) (Harlan Olac, Bicester, U.K) were sacrificed and the cerebella collected. Meninges and pedacles were removed and the cerebella stored in Hanks Balanced Salt Solution (Imperial Laboratories, Andover, UK). The tissue was lacerated and immersed in 3 ml of 0.02% Na 2 EDTA (Sigma) for 5 min at 37 C and disaggregated using a siliconised pasteur pipette and re-suspended in 4 ml of fresh 0.02% Na 2 EDTA solution. Further disaggregation was performed by repeated trituration using siliconised pipettes of reduced aperture (0.5-0.3 mm). The resultant cell suspensions were pooled and centrifuged for 3 mins in a microfuge and the cell pellet re-suspended in fresh cell culture media (DMEM/F12, 1:1; 10% FCS (w/v); 0.6% glucose; 5 mM HEPES; 25 mM KCl). Tissue culture flasks were coated with poly-L-lysine (15 mg ml 1 ) for 45 mins at room temperature and washed once in PBS before use. The cell suspension was filtered through a 40 m mesh and plated at a density of 1.5 10 5 cells cm 2 .
Retinoic acid treatment
Retinoic acid (1 M) (Sigma) was added to NG108-15, ND7/23, NTera-2 cell cultures and primary rat cerebella granule neurone cultures (P/GNC) for 2 weeks to enhance the differentiation of these cells into neuronal cells as previously described by other workers (Pleasure and Lee, 1993) .
Direct injection of RAd35 into Balb/c mouse brain
Three pairs of three week old Balb/C mice (Harlan Olac, Bicester, U.K) were intracranially injected with either 1.5 10 8 pfu/dose of RAd35, 1.5 10 
Assay for -galactosidase
Direct histological staining was performed with the chromogenic substrate 5-bromo-4-chloro-3-indoyl--D-galactosidase (X-gal) to detect the expression ofgalactosidase in either cultured cells or brain tissue sections. Cells were grown as monolayers, washed once with phosphate buffered saline and fixed with 0.5% (v/v) gluteraldehyde for 15 minutes at room temperature. Each cell monolayer or mouse brain section was stained in 2% (w/v) X-gal in staining solution (final conc: 3 mM potassium ferricyanide; 3 mM potassium ferrocyanide; 1.3 mM magnesium chloride) in 1x PBS and incubated at 37 C for 2 to 3 h. The cells were examined using light microscopy (Warnes and Fooks, 1996) .
Results
In Table 1 ). Neuronal, glial, astrocytoma and medulloblastoma cell lines expressed -galactosidase in vitro following infection with RAd35 at an m.o.i of 100 pfu/cell (Table 1) . Levels of -galactosidase expression in all the human cell lines derived from the CNS were also over 50%. In contrast, the rodent cell lines showed lower levels of expression, ranging between 10 and 50%. The expression in the mouse brain tumour cell line (BC3H1) was between 10 and 50% and for the rat neuronal cell line (B50) the lowest levels of -galactosidase expression were observed (less than 10%). However, the expression of -galactosidase in the hybrid cell lines (formed by the fusion of rat and mouse neuronal or glial cells) NG108-15 and ND7/23 exceeded 50%. Cell lines ND7/23, NG108-15 and NTera 2 induced by retinoic acid showed morphological changes consistent with the differentiation of neuronal cells (see Fig. 1 ). Normally, the cell lines ND7/23 and NG108 are weakly adherent to plastic, however, it was found that approximately 75% of the cells became adherent to plastic after induction with 1M retinoic acid. The ND7/23 and NTera2 cells showed many large flat cells at low density cultures. The differentiation was marked by the appearance of several axonal processes and inter-cellular connections compared to un-treated cells. Most of the non-differentiated cells (about 25% in the entire culture) aggregated to form cell clusters.
The ability of retinoic acid to induce a rodent primary cell culture (P/GNC) was also investigated. The growth of P/GNC cells in retinoic acid treated cultures showed the increased appearance of cells resembling neurons. The cells formed a typical meshwork of axonal-like structures with no further observed proliferation. Expression of -galactosidase expression in two differentiated cell lines, ND7/23 and NG108 was up to 90%. Similarly, NTera-2 cells expressed -galactosidase but the proportion of cells positively staining did not increase with retinoic acid treatment. However, the entire P/GNC cell monolayer stained positively representing a high level of -galactosidase expression in retinoic acid treated primary rat neurons.
In vivo -galactosidase gene transfer
The ability of the replication deficient adenoviral vector to transfer the foreign gene (-galactosidase) into cells was analysed by the direct in vivo administration of RAd35 into the brains of Balb/c mice. There was no adverse effect of inoculation with RAd35, RAd31 or PBS on the animal's health and behaviour up to 120 h post infection when the animals were sacrificed. Histological analysis of the infected brain after 120 h post infection revealed the expression of -galactosidase in the tissue cell sections, previously infected with RAd35. In contrast, there was no expression ofgalactosidase detected in the controls (RAd31 or PBS injected mouse brain). The histological appearance of the inoculated mouse brain is shown in Figure 2 .
Discussion
Adenovirus vectors have become an increasingly common viral vector expression system for use in both novel vaccine design (Fooks et al., 1995) and for in vivo gene delivery into the brain .
The in vitro results from the immortalised cell lines have shown that RAd35 infected a range of different cells from the CNS. The cell lines derived from CNS (including neuronal and glial cells) expressed -galactosidase following infection with a low m.o.i of RAd35. Our results confirm those from other groups who demonstrated that replication-deficient adenovirus vectors are capable of infecting a variety of cell types (Caillaud et al., 1993) . This data confirms the efficient delivery of the reporter gene in RAd35 infected cells and that adenoviruses have a wide tissue tropism. In CNS tissue, this property may have useful gene therapy applications in which adenoviruses are required to non-specifically replace a single gene deletion in a variety of cell types. Expression of adenoviral mediated -galactosidase in primary cells or rat neuronal cells was low; this may be due to the absence of relevant receptors on these cells for the entry of RAd35 or the inability to incorporate the delivered gene by these neuronal cells. Other studies have shown adenoviruses have species specificity in cell culture (Lowenstein et al., 1996) .
Retinoic acid induced cells (NG108/15, ND7/23, NTera-2 and P/GNC) produced a monolayer exhibiting extended axonal processes indicative of neuronal differentiation. Currently, it is not well understood why certain cell lines should respond to retinoic acid (Cotte et al., 1982) . However, it is believed that retinoic acid mimics naturally occurring retinoids or other agents which complement cell differentiation in vivo. Expression of -galactosidase by differentiated cells confirmed the ability of adenoviruses to efficiently deliver the cloned gene into terminally differentiated nondividing cells including neurons. Expression levels increased in retinoic acid treated cells in two of the four cell lines tested. The ability of adenoviruses to show enhanced infection in cells induced to differentiate by retinoic acid demonstrates a distinct advantage over retroviral vectors, which cannot efficiently be used for neurological gene therapy as they will not infect terminally differentiated cells in the CNS (Kozak, 1985) .
In contrast to the in vitro results obtained in rodent cell lines following infection with RAd35, the in vivo studies performed in the murine model suggest that adenovirus can transfer foreign genes into a significant number of brain cells after a single injection. Expression of -galactosidase was detected predominantly in cells within the proximity of the needle track in the brain parenchyma. Direct injection of RAd35 into the brain suggests that the spread of the virus from the inoculation site was relatively limited. This may be due to the defective nature of RAd35 which is incapable of lateral spread in CNS related cells. Similarly, other workers have shown that adenoviruses can deliver a transgene, by direct injection into areas of the rodent brain for the therapeutic gene therapy of malignant tumours by expressing a toxic gene product (Badie et al., 1994; Brody et al., 1994) . The absence of any detectable adverse side-effects in the mice that were infected following the direct stereotactic administration of replication-deficient adenoviruses into the brain may be an important safety feature for the future use of these vectors in human gene therapy trials. How-ever, the direct stereotactic injection of viruses into the brain may circumvent the host's immune responses as viruses can remain latent in neurons and often evade cellular immune responses in the CNS. Immune cells (mainly cytotoxic T-lymphocytes) within the systemic blood circulation have the ability to cross the blood brain barrier and enter the central nervous system (von Herrath et al., 1995) . We hypothesise that the CTL response cannot efficiently target the infected neurons to clear the virus due to the restricted low level expression of MHC antigens on CNS cells (Lampson, 1987) .
Replication-deficient adenoviral vectors offer a safety advantage compared to replication-competent viral vectors due to the lack of adenoviral proteins expressed from the viral genome and high level protein expression from a strong constitutive eukaryotic promoter (reviewed in Wilkinson, 1994; Fooks et al., 1995) . Further developments of new generation adenovirus vectors containing deletions in the virus genome have improved the prospect of using adenoviruses for in vivo human gene therapy (Yang et al., 1994) .
Initially, adenovirus recombinants were first used to treat patients suffering from cystic fibrosis by replacing the cystic fibrosis transmembrane regulator gene (Rosenfield et al., 1992) . However, adenoviruses have been shown to produce deleterious side-effects including inflammation when the input virus is sufficiently large enough to produce either a high level of cytokine activity or possibly a significant anti-adenovirus T-cell response (Ginsberg, 1996) . Furthermore, adenovirus vectors were shown to be removed by the host's cellular and immune responses which may lead to both transient gene expression and the inability to re-administer the virus. However, other workers have demonstrated that the stability of gene expression is dependant on the immune responses which are directed against the transgene and not expression from the adenoviral genome (Tripathy et al., 1996) .
The successful introduction of foreign genes into neuronal cells may lead to a dramatic improvement in controlling genetic diseases in which only a minority of cells are required for genetic alteration in order to replace a deficient enzyme and therefore correct the disorder i.e. 'enzyme replacement therapy'. Currently, we are investigating the use of this delivery system as a tool for replacing missing or damaged genes in cells of the CNS. However the progress in clinical neurological therapy will be dependent on the safety and the further development of second generation adenovirus vectors for use in human clinical trials. This study demonstrates the potential application of replication-deficient adenovirus vectors to deliver genes into a variety of CNS cells. It has also identified a panel of immortalised cell lines which mimic the responses of primary neurons to infection from a replication-deficient adenovirus vector. To address the problems of cell specificity and tissue tropism, we are currently constructing adenovirus vectors containing tissue-tropic neuronal promoters expressing greenfluorescent protein to investigate the promoter specificity in a particular cell type of the central nervous system.
